ESMO 2024: Treatment Breakthroughs in Pretreated Patients with Advanced or Metastatic NSCLC With or Without Actionable Genomic Alterations - Episode 2
Optimizing Treatment for Advanced EGFR-Mutated NSCLC: FLAURA2, Toxicity Management, and ctDNA
This episode delves into expert perspectives on the safety and tolerability of combining osimertinib with chemotherapy in untreated, advanced EGFR-mutated NSCLC, resistance to third-generation EGFR TKIs, the superiority of concurrent versus sequential therapy from the FLAURA2 study, the role of ctDNA in managing additional EGFR mutations, and decision-making in utilizing FLAURA2 for treatment selection.
Video content above is prompted by the following:
- For most patients with untreated, advanced, or metastatic EGFRmut+ NSCLC do you consider the combination of osimertinib and chemotherapy to be manageable from a safety and tolerability perspective?
- In your experience, how soon do patients become resistant to a third-generation, EGFR TKI?
- Based on the FLAURA2 study design, do you consider concurrent combination therapy superior to sequential treatment for the population of patients with untreated, advanced, metastatic, or recurrent NSCLC not amenable to resection or radiotherapy?
- Please explore the implications of additional mutations in patients with EGFRmut+NSCLC and the occurrence of EGFR mutations on ctDNA after treatment with osimertinib.
- How are you using ctDNA in decision making and practice among these patients with EGFR mutated NSCLC for osimertinib and chemo + ostimertinib?